CORRECTING and REPLACING Flatiron Health Announces Research to Be Presented at ASCO 2025
NEW YORK--(BUSINESS WIRE)--Please remove the partners listed under "Real-world (rw) ctDNA testing trends and associated outcomes in patients (pts) with early stage breast cancer (EBC)."
Our research accepted at this year's ASCO demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer.
Share
The updated release reads:
FLATIRON HEALTH ANNOUNCES RESEARCH TO BE PRESENTED AT ASCO 2025
Flatiron's 2025 ASCO research showcases the power of longitudinal, real-world oncology data and innovative AI-driven methodologies to generate actionable evidence, address health equity, and accelerate progress in cancer care and clinical research.
Flatiron Health today announced 14 abstracts leveraging its high-quality real-world oncology data have been accepted for poster presentation and online publication at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. These studies exemplify Flatiron's commitment to advancing cancer research and align with this year's ASCO theme, 'Driving Knowledge to Action: Building a Better Future,' by delivering critical evidence to inform and improve patient care.
'AI and related technologies have enabled us to unlock data and insights from our entire network of over five million people with cancer, providing unprecedented scale, efficiency, and innovation for both real-world evidence generation and clinical trial execution,' said Stephanie Reisinger, Senior Vice President & General Manager, Real-World Evidence. 'Our research accepted at this year's ASCO demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer.'
Highlights include:
a poster presentation utilizing advanced machine learning models to identify a cohort of over 195,000 to complete the largest real-world study to date examining ctDNA testing in early stage breast cancer
an abstract assessing how often PSMA-PET scans were used among non-Latinx/Hispanic White, Black, and Latinx patients with metastatic prostate cancer
an abstract demonstrating the potential of a centralized, tech-enabled screening service to make clinical trial enrollment and more efficient, particularly in community oncology settings
Schedule a meeting with Flatiron Health at ASCO 2025, and learn more about our abstracts and events, including workshops and panels.
Follow Flatiron Health on X and LinkedIn for more updates from #ASCO25 and visit us in person at Booth #11131.
Partners: Memorial Sloan Kettering Cancer Center, AstraZeneca
Dana Rathkopf, Danni Zhao, Lana Kovacevic, Jenna Collins, Eunice Hankinson, Helen Marshall, Aaron Springford, Simran Shokar, Helene von Bandemer, Weiyan Li
Genitourinary—Prostate, Testicular, and Penile
Poster board: 295
Abstract number: 5096
Impact of social determinants of health on mortality in diffuse large B-cell lymphoma (DLBCL) using real-world data Partners: Yale School of Medicine, University of Alabama at Birmingham, Fox Chase Cancer Center, University of Texas Southwestern Medical Center, University of Colorado at Anschutz
Maureen Canavan, Mengru Wang, Olive Mbah, Maneet Kaur, Michael J. Hall, Adeel Khan, Jessica McDermott, Madeline Schmitter, Anosheh Afghahi, Gaurav Goyal
Quality Care/Health Services Research
Poster board: 436
Abstract number: 11097
Partners: UCLA, AstraZeneca, Memorial Sloan Kettering Cancer Center, The University of Chicago
Jay Lee, Daniel Simmons, Tiernan Mulrooney, Jeremy Snider, Lana Natalija Kovacevic, Karen Schwed, Aditya Juloori
Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Poster board: 199
Abstract number: 8078
Molecular residual disease (MRD) in solid tumors Partners: Taylor Cancer Research Center, Exact Sciences, Case Comprehensive Cancer Center
Majd T. Ghanim, John Nemunaitis, Tara Marti, Abhishek Dabral, Katherine Diaz-MacInnis, Judith Frederick, Marla Kuleszynski, Yichen Lu, Amanda Rodriguez-Sullivan, Melanie Palomares, Natalie Salituro, Soma Subramaniam, Anthony Tate, Kathleen Turnbull, Neal J. Meropol
Therapeutics—Molecularly Targeted Agents and Tumor Biology
Poster board: 486b
Abstract number: TPS3186
Assessment of racial/ethnic inequities in uptake of Prostate Specific Membrane Antigen - Positron Emission Tomography (PSMA-PET) scans among patients with metastatic prostate cancer in the United States (US) Eunice A. Ochuonyo, Samantha Reiss, Patrick J. Ward, Brooke A. Jarrett, Olive Mbah, Prakirthi Yerram, Laura Rivera-Reyes, Sophia Miller, Kelly Magee, Lynn Rosario, Wendy Wittman, Cleo A. Ryals
Online publication only
Accrual of racially and ethnically underrepresented populations with multiple myeloma associated with centralized patient screening in a multicenter study Partners: University of Colorado, Johnson & Johnson, New York Cancer and Blood Specialists
Anosheh Afghahi, Daniel Sanchez, Yichen Lu, Richard M. Zuniga, Laura Heste, Dina Gifkins, Britney Beaulieu, Catharine Cipolla, Barry Leybovich, Debra Mitchell, Jeffrey Nan, Ebube Onwasigwe, Hemang Patel, Paul Salcuni, Chloe Salzman, Neal J. Meropol, Ashita S. Batavia
Online publication only
A retrospective real-world study of first-line PD-(L)1 inhibitor use in patients with metastatic non-small cell lung cancer (mNSCLC) Partner: Incyte
Kim Saverno, Siobhan Halloran, Mark Guinter, Kelly Magee, Michael Ondovik, J.E. Hamer-Maansson, Mark Cornfeld, Mihaela Munteanu
Online publication only
A retrospective cohort study of real-world clinical outcomes in patients with CLL/SLL previously treated with covalent BTK inhibitor (cBTKi) and BCL2 inhibitor (BCL2i) regimens Partners: Merck & Co, MSD UK, Mayo Clinic
Jennifer Prescott, Christina Parrinello, Ahmed Sawas, Enrico De Nigris, Jing Yang, Erik Bloomquist, Indu Shrivastava, Changxia Shao, Xinyue Liu, Mohammed Farooqui, Sameer A. Parikh
Online publication only
Management and outcomes of rash, peripheral neuropathy (PN), and hyperglycemia (HG) during first-line (1L) treatment (Tx) of locally advanced/metastatic urothelial cancer (la/mUC) in a real-world setting Partners: Cleveland Clinic, Merck KGaA, EMD Serono
Amanda Nizam, Mairead Kearney, Valerie Morris, Seyed Hamidreza Mahmoudpour, Carroline Lobo, Chiemeka Ike, Jason Hoffman, Ilian Iliev, Prakirthi Yerram, Mark Guinter
Online publication only
Concordance of response-based clinical trial and machine learning–generated real-world end points Partner: Genentech
Qianyi Zhang, Konstantin Krismer, Yichen Lu, Qianyu Yuan, Aaron Dolor, Auriane Blarre, Aaron B. Cohen, Tori Williams, Sophia Maund, Minu K. Srivastava, Kelly Magee
Online publication only
Partners: Pfizer, University of San Francisco Helen Diller Family Comprehensive Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, European Institute of Oncology IRCCS, University of Milano, UPMC Hillman Cancer Center
Hope S. Rugo, Rachel M. Layman, Filipa Lynce, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B. Cohen, Melissa Estevez, Giuseppe Curigliano, Adam Brufsky
Online publication only
Unmet need in adults and adolescents and young adults (AYAs) with B-cell acute lymphoblastic leukemia (B-ALL) in the US following a second relapse Partners: Memorial Sloan Kettering Cancer Center, Stanford Cancer Center, AstraZeneca, Tampa General Hospital Cancer Institute, Knight Cancer Institute, MD Anderson Cancer Center
Mark B. Geyer, Michaela Liedtke, Vikram Shetty, Anthony Proli, Yazan K Barqawi, Jenna Collins, Nikesh N. Shah, Jessica T. Leonard, Joseph Elias Jabbour
Online publication only
About Flatiron
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
5 hours ago
- Business Wire
Rocket Lab Completes Record Launch Turnaround From Launch Complex 1, Successfully Deploys 68 th Electron Mission
MAHIA, New Zealand--(BUSINESS WIRE)--Rocket Lab Corporation (Nasdaq: RKLB) ('Rocket Lab' or 'the Company'), a global leader in launch services and space systems, today successfully launched its 68th Electron rocket to deploy a single satellite to space for a confidential commercial customer. The mission was the second of two launches from the same launch site in less than 48 hours, a new launch record for the Company as it continues to deliver dedicated, repeatable and reliable access to space for satellite operators. The 'Symphony In The Stars' mission lifted-off from Rocket Lab Launch Complex 1 in Mahia, New Zealand on June 28 th (7:08 p.m./07:08 UTC) to deploy a single spacecraft to a 650km circular Earth orbit. The mission was the first of two dedicated launches for the new customer on Electron booked less than four months ago, with a second mission scheduled before the end of 2025. Rocket Lab has now completed four launches in June for commercial satellite constellation operators, underscoring Electron's consistent performance and rapid deployment capabilities as the world's leading small launcher: the 'Full Stream Ahead' mission on June 3 rd; 'The Mountain God Guards' mission on June 11 th; 'Get The Hawk Outta Here' launched on June 26 th UTC, and today's 'Symphony In The Stars' mission. Rocket Lab Founder and CEO, Sir Peter Beck, says: 'Electron has demonstrated once again that it is the gold standard for responsive and reliable space access for small satellites. The future of space is built on proven performance, and Electron continues to deliver against a stacked launch manifest this year. Congratulations to the team on achieving its fastest launch turnaround yet between two missions from Launch Complex 1. This launch was also a quick-turn mission to meet our customer's mission requirements, and we're looking forward to doing it again later this year.' 'Symphony In The Stars' was Rocket Lab's tenth Electron mission of 2025 and its 68th launch overall. With 100% mission success so far this year, Electron continues to deliver reliable deployment amid an increasing launch cadence and rapid contract-to-launch timelines. Launch images: About Rocket Lab Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, satellite manufacture, spacecraft components, and on-orbit management solutions that make it faster, easier, and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle, a family of spacecraft platforms, and the Company is developing the large Neutron launch vehicle for constellation deployment. Since its first orbital launch in January 2018, Rocket Lab's Electron launch vehicle has become the second most frequently launched U.S. rocket annually and has delivered over 200 satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab's spacecraft platforms have been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third launch pad in Virginia. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward looking statements contained in Section 27A of the Securities Act of 1933, as amended (the 'Securities Act') and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy are forward-looking statements. The words 'believe,' 'may,' 'will,' 'estimate,' 'potential,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'strategy,' 'future,' 'could,' 'would,' 'project,' 'plan,' 'target,' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the 'SEC'), accessible on the SEC's website at and the Investor Relations section of our website at which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Associated Press
7 hours ago
- Associated Press
Mr. Gad Forced to Once Again Set the Record Straight at Paragon – Hopefully For the Last Time
Encourages All Stockholders to Vote on the BLUE Proxy Card Ahead of the Company's Annual Meeting NEW YORK, NY / ACCESS Newswire / June 27, 2025 / Hesham 'Sham' Gad, who beneficially owns approximately 28.2% of the outstanding shares of common stock of Paragon Technologies, Inc. ('Paragon' or the 'Company') (OTC PINK:PGNT) and is Paragon's largest stockholder, today issued a statement regarding the incumbent directors' latest, desperate attempt to avoid accountability and mislead stockholders ahead of the Company's upcoming 2025 Annual Meeting: 'This morning, less than one business day before the Company's Annual Meeting, I was informed that the incumbent directors wanted to immediately dispense with over $500,000 of the Company's cash to purchase insurance. The urgency and timing of this decision raise serious concerns. Think about this: why would directors - who own little equity and may not be elected at the Annual Meeting on Monday - call an immediate board meeting to cause Paragon to spend this much shareholder money? This latest move appears to follow a troubling pattern. From implementing a poison pill and issuing stock grants, to now spending hundreds of thousands of shareholder dollars on a last-minute policy, the actions of this Board increasingly seem aimed at shielding themselves rather than serving the long-term interests of Paragon and its owners. Our shareholders know better - this is not about them, but simply another effort, to benefit these directors at shareholder expense. It is disappointing, though not surprising, to see the current Board of Paragon once again resort to misinformation and personal attacks to avoid accountability. To be clear, I have never objected to the Company having reasonable D&O insurance policies, and in fact, we have had sufficient coverage for years evidenced by the simple fact that for over a decade Paragon has NEVER had single D&O claim under my leadership. What has changed is not the Company's exposure, but the risks introduced by the behavior of this Board. On the other hand, as a significant stockholder, I care very deeply about protecting the Company from BOTH risk and wasteful spending - two elements this Board has exposed the Company to in spades. The Board in hastily approving this self-serving purchase disregarded the Company's own governing documents, our settlement agreement, and potentially their fiduciary duties. In doing so, they continue to validate why they are so out of touch with Paragon shareholders. As such, it was vital I advised them of their violations and potential liability exposure. This Board has used substantial Company resources first to entrench themselves, then to defend that entrenchment, and now, just days before the Annual Meeting, to attempt to insulate themselves from the consequences of their poor leadership. As we approach the Annual Meeting, this episode highlights exactly why change is needed. We need leadership that focuses on transparency, fiscal responsibility, and long-term value - not self-preservation. We encourage our fellow stockholders to continue voting on the BLUE card for a slate of directors that values transparency, progress and fulfilling its obligation to act in the best interest of stockholders. We thank you for your consideration and support to date. Let's work together to build something stronger - for today and for the future.' PLEASE VOTE YOUR BLUE PROXY CARD TODAY. Further information and resources in connection with Mr. Gad's campaign for change, accountability and a stockholder-first culture at Paragon are available at For inquiries, please reach out to the address below: [email protected] Saratoga Proxy Consulting LLC John Ferguson (212) 257-1311/(888) 368-0379 [email protected] SOURCE: Sham Gad press release
Business Wire
16 hours ago
- Business Wire
KBRA Releases Research – Potential OBBBA Implications for Litigation Finance ABS
NEW YORK--(BUSINESS WIRE)--KBRA releases research examining the potential implications for litigation finance ABS stemming from proposed measures under the Tackling Predatory Litigation Funding Act (TPLFA), which is currently included in the U.S. Senate's One Big Beautiful Bill Act (OBBBA). Litigation finance has a long history and, in recent years, has established itself as a niche segment in the asset-backed securities (ABS) market. However, the TPLFA could significantly alter the economics of this evolving structured finance asset class, as it proposes substantial new taxes on profits from third-party litigation funding. Litigation finance ABS transactions, which are typically backed by nonrecourse advances to plaintiffs in personal injury and other civil cases, could face meaningful structural and liquidity challenges if the legislation is enacted. Click here to view the report. Related Publication Litigation Finance ABS: Not Settling for Less About KBRA KBRA, one of the major credit rating agencies, is registered in the U.S., EU, and the UK. KBRA is recognized as a Qualified Rating Agency in Taiwan, and is also a Designated Rating Organization for structured finance ratings in Canada. As a full-service credit rating agency, investors can use KBRA ratings for regulatory capital purposes in multiple jurisdictions. Doc ID: 1010181
